Escape Bio, a developer of treatments for genetic neurodegenerative diseases, has raised $73 million in financing. Wellington Management Company LLP led the round with participation from other backers that included Avidity Partners, CAM Capital, New Leaf Ventures, Rock Springs Capital, Surveyor Capital, Sphera Funds Management, OrbiMed, Novo Holdings, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners and Sutter Hill Ventures.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: